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The present observational study aimed to evaluate the clinical eﬀectiveness of vildagliptin with metformin in Korean patients with
type 2 diabetes mellitus (T2DM). Data were pooled from the vildagliptin postmarketing survey (PMS), the vildagliptin/metformin
ﬁxed drug combination (DC) PMS, and a retrospective observational study of vildagliptin/metformin (ﬁxed DC or free DC). The
eﬀectiveness endpoint was the proportion of patients who achieved a glycemic target (HbA1c) of ≤7.0% at 24 weeks. In total, 4303
patients were included in the analysis; of these, 2087 patients were eligible. The mean patient age was 56.99± 11.25 years. Overall,
58.94% patients achieved an HbA1c target of ≤7.0% at 24 weeks. The glycemic target achievement rate was signiﬁcantly greater in
patients with baseline HbA1c< 7.5% versus ≥7.5% (84.64% versus 43.97%), receiving care at the hospital versus clinic (67.95%
versus 52.33%), and receiving vildagliptin/metformin ﬁxed DC versus free DC (70.69% versus 55.42%). Multivariate logistic
regression analysis indicated that disease duration (P < 0 0001), baseline HbA1c (P < 0 0001), and DC type (P = 0 0103) had
signiﬁcant eﬀects on drug eﬀectiveness. Vildagliptin plus metformin appeared as an eﬀective treatment option for patients with
T2DM in clinical practice settings in Korea.
1. Introduction
Type 2 diabetes mellitus (T2DM) is a well-established disease
that causes disability (blindness, limb amputation, kidney
failure, or cardiovascular events) in aﬀected patients [1].
Since 1980, the age-adjusted prevalence of diabetes in adults
has increased, which has resulted in quadrupling of the num-
ber of aﬀected adults with diabetes in countries worldwide
[2]. The burden of diabetes, both in terms of prevalence
and number of adults aﬀected, has rapidly increased in East
Asian countries, including Korea [2, 3].
Among oral hypoglycemic agents (OHAs), dipeptidyl
peptidase 4 (DPP-4) inhibitors are classiﬁed as a relatively
new category which produce eﬀects by increasing the con-
centration of active forms of incretin, such as glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotropic
peptide (GIP). Thus, DPP-4 inhibitors can reduce fasting
and postprandial blood glucose levels through eﬀects on
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incretins by consequently increasing both α- and β-cell
sensitivities to glucose levels [4]. The use of DPP-4 inhibitors
in patients with T2DM has markedly increased in clinical
practice because these are generally weight neutral and have
a low risk of hypoglycemia [5]. The American Diabetes Asso-
ciation (ADA) and European Association for the Study of
Diabetes (EASD) guidelines suggest the use of metformin as
a ﬁrst-line drug treatment and recommend the addition of
a second drug if glycemic control is not achieved within the
target levels [6]. In contrast to EASD/ADA, Japanese Diabe-
tes Society (JDS) allows the use of any antidiabetic drugs that
are appropriate to the pathophysiology of patient’s diabetes
[7]. Based on the guideline and potential, the incretin-based
drug especially DPP-4 inhibitor is considered as a ﬁrst choice
therapy in Japanese type 2 diabetes patients [8]. Among
DPP-4 inhibitors, vildagliptin is known to be an eﬀective
and safe therapeutic option for patients with T2DM, both
as monotherapy and in combination with other medications
[9]. Although the eﬃcacy and safety of vildagliptin as mono-
therapy, dual therapy (particularly as an add-on to metfor-
min), and triple therapy have been proven in randomized
clinical trials (RCTs) [9], data regarding the eﬀectiveness of
vildagliptin in clinical practice settings, particularly in Korea,
are scarce. Therefore, based on a pooled analysis of three
studies conducted in clinical practice settings, we aimed
to assess the glycemic eﬀectiveness of vildagliptin plus
metformin treatment in Korean patients with T2DM (the
VICTORY study).
2. Methods
We pooled and analyzed data retrieved from prospective,
phase 4, postmarketing surveillance (PMS) studies for
vildagliptin and vildagliptin/metformin ﬁxed drug combina-
tion (DC) as well as from a retrospective study of vildaglip-
tin/metformin (ﬁxed or free DC) (the VICTORY study).
The primary endpoint of vildagliptin and vildagliptin/met-
formin ﬁxed DC PMS studies was safety analysis. These were
noninterventional “real-world” studies without any deﬁned
study-related procedures and were sponsored by Novartis
Korea and conducted after the corresponding protocols were
approved by the Ministry of Food and Drug Administration
and institutional review board (IRB) (Severance Hospital,
IRB number: 4-2010-0800). The retrospective observational
study of vildagliptin/metformin, considered in the present
analysis, was conducted after its protocol was approved by
the IRB (Ulsan University Hospital, IRB number: 2012-
075). The present study was conducted in accordance with
the ethical principles stated in the Declaration of Helsinki
and in compliance with the International Conference on
Harmonization-Good Clinical Practice guidelines, as revised
in 2013. Informed consent was obtained from all patients
included in these studies. The study population comprised
Korean individuals aged≥ 19 years with T2DM, who were
prescribed vildagliptin +metformin as combination therapy
with or without other drug(s) in the form of add-on or initial
combinations or vildagliptin/metformin as ﬁxed DC. Exten-
sive exclusion criteria were applied for this study. Details
regarding inclusion and exclusion criteria of each of the
studies are summarized in Supplementary Table S1 available
online at https://doi.org/10.1155/2017/5282343.
The duration of the study was 24 weeks. At baseline,
demographic data regarding gender, age, weight, treatment
center type, concurrent disease, concomitant medication,
medical history, duration of diabetes, and DC type were
collected. In addition, laboratory data were collected at base-
line, after an interim of 12 weeks, and at the ﬁnal visit
(approximately 24 weeks after the baseline visit). For eﬀec-
tiveness analysis, the achievement rate of the glycemic target
(HbA1c≤ 7.0%) at 24 weeks was assessed as the primary
outcome. Secondary outcomes included changes in HbA1c
levels and fasting plasma glucose levels at weeks 12 and 24.
All endpoints are descriptively summarized at each visit.
Continuous variables are expressed using descriptive
statistics (n, mean± SD), whereas discrete variables are
summarized using frequency tables (n, %). We conducted
chi-square tests and t-tests to evaluate diﬀerences between
the groups. Multivariate regression analysis was used to
determine correlations between the HbA1c target achieve-
ment rate and gender, age, weight, concurrent disease,
medical history, concomitant medications, duration of
disease, baseline HbA1c, and DC type. All data were analyzed
using SAS (version 9.4, SAS Institute Inc., Cary, NC), and
P values < 0.05 were considered statistically signiﬁcant.
3. Results
A total of 4303patientswho received treatmentwith vildaglip-
tin at least once constituted the full analysis set in the three
pooled studies (3294 from the vildagliptin PMS, 726 from the
vildagliptin/metformin ﬁxed DC PMS, and 283 from the
vildagliptin retrospective study); of these, 2216 patients were
excluded for the following reasons: violation of inclusion/
exclusion criteria and/or the instructions regarding dosage
and administration (n = 349), prescription of vildagliptin
alone (n = 28), no documented baseline HbA1c (n = 475),
and no documented HbA1c at 24 weeks (n = 1364) (Figure 1).
3.1. Baseline Characteristics according to Achievement of
Target HbA1c Levels at 24 Weeks. Baseline characteristics of
the study patients are presented in Table 1. The mean age
and diabetes duration were 57 years and 6.24 years, respec-
tively. Men accounted for 54.8% of the study population.
Approximately 94% of patients were receiving dual therapy
of vildagliptin and metformin. To identify the clinical factors
that could aﬀect the glycemic target achievement rate, the
patients were divided into two groups according to achieve-
ment of the target HbA1c level of 7.0% at 24 weeks: good
responder group I (HbA1c≤ 7.0%; n = 1230; 695 men, 535
women) and nonresponder group II (HbA1c> 7.0%;
n = 857; 449 men, 408 women). Overall, 58.9% of patients
achieved the glycemic target (HbA1c≤ 7.0%) at 24 weeks.
No signiﬁcant diﬀerences were noted in terms of gender or
age between the groups. The duration of diabetes was signif-
icantly longer in group II (5.1 years in group I versus 7.7
years in group II). Moreover, the healthcare facility at which
treatment was received also signiﬁcantly diﬀered between the
groups (Table 1).
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Figure 1: Flow diagrams of patient disposition. PMS: postmarketing survey; retro OS: retrospective observational study.
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Table 1: Baseline patient characteristics according to HbA1c levels at 24 weeks.
HbA1c≤ 7.0% at 24 weeks
(N = 1230)
HbA1c> 7.0% at 24 weeks
(N = 857)
Total
(N = 2087) P value
Gender, n (%)
Male 695 (56.5) 449 (52.4) 1144 (54.8) 0.0633a
Age (years)
Mean± SD 56.8± 11.0 57.3± 11.7 57.0± 11.3 0.2517b
Weight (kg)
N 1092 778 1870
Mean± SD 67.5± 11.0 66.3± 10.9 67± 11.0 0.0215b
Baseline HbA1c, n (%)
<7.5% 650 (52.9) 118 (13.8) 768 (36.8) <0.0001a
≥7.5% 580 (47.2) 739 (86.2) 1319 (63.2)
Elderly group, n (%)
<65 years 926 (75.3) 611 (71.3) 1537 (73.7) 0.0418b
≥65 years 304 (24.7) 246 (28.7) 550 (26.4)
Treatment center type, n (%)
Hospital 600 (48.8) 283 (33.0) 883 (42.3) <0.0001b
Clinic 630 (51.2) 574 (67.0) 1204 (57.7)
Concurrent disease, n (%)
Yes 700 (56.9) 449 (52.4) 1149 (55.1) 0.0412b
No 530 (43.1) 408 (47.6) 938 (44.9)
Medical history, n (%)
Yes 153 (12.4) 83 (9.7) 236 (11.3) 0.0296b
No 1036 (84.2) 756 (88.21) 1792 (85.9)
Concomitant medications
(except for diabetes medications), n (%)
Yes 733 (59.6) 448 (52.3) 1181 (56.6) 0.0009b
No 497 (40.4) 409 (47.7) 906 (43.4)
Duration of T2DM (years)
n 1067 785 1852
Mean± SD 5.1± 5.3 7.7± 6.0 6.2± 5.8 <0.0001a
Drug combination type, n (%)
Vildagliptin +metforminc 895 (72.8) 720 (84.0) 1615 (77.4) <0.0001b
Vildagliptin/metformin FDCd 299 (24.3) 124 (14.5) 423 (20.3)
Pharmacotherapy at baseline, n (%)
Second-line therapy 1181 (96.0) 775 (90.4) 1956 (93.7) <0.0001b
Third- or further-line therapy 43 (3.5) 76 (8.9) 119 (5.7)
ΔHbA1c (%)
12 weeks
N 923 699 1622
Mean± SD −0.9± 1.1 −0.6± 1.2 −0.8± 1.2 <0.0001b
24 weeks
N 1230 857 2087
Mean± SD −1.2± 1.2 −0.8± 1.3 −1.0± 1.3 <0.0001b
ΔFBG (mg/dL)
12 weeks
N 535 359 894
Mean± SD −30.9± 47.1 −24.2± 57.7 −28.2± 51.7 0.0673b
24 weeks
N 663 406 1069
Mean± SD −32.6± 48.8 −23.0± 60.2 −29.0± 53.6 0.0068b
SD: standard deviation; T2DM: type 2 diabetes mellitus; FDC: ﬁxed drug combination; FBG: fasting blood glucose. aChi-square test. bt-test. cVildagliptin +
metformin free drug combination. dVildagliptin/metformin ﬁxed dose combination.
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3.2. Glucose-Lowering Eﬀectiveness according to Baseline
Characteristics. In this analysis, the HbA1c levels decreased
from 8.0± 1.4% at baseline to 7.0± 1.0% at the 24-week
endpoint, which resulted in a signiﬁcant reduction of
1.0± 1.3%. We also compared glucose-lowering eﬀective-
ness according to baseline characteristics. With regard to
the DC type, the proportion of patients who achieved
the target HbA1c was signiﬁcantly greater in those treated
with vildagliptin/metformin ﬁxed DC compared with those
treated with the free DC regimen (70.7% versus 55.4%).
With regard to the healthcare facility at which treatment
was received, the proportion of patients who achieved
the glycemic target was greater in the hospital group than
in the clinic group (68.0% versus 52.3%). Patients with
baseline HbA1c< 7.5% showed a higher glycemic target
achievement rate than patients with baseline HbA1c≥ 7.5%
(84.6% versus 44.0%). Overall, 60.3% of patients aged< 65
years achieved the glycemic target, whereas 55.3% of
patients aged≥ 65 years achieved the glycemic target at
24 weeks (Figure 2). The results of multivariate logistic
regression models are presented in Table 2. After adjusting
for other covariates, including gender, age, weight, concur-
rent disease, medical history, and concomitant medica-
tions, multivariate logistic regression analysis indicated
that patients with lower baseline HbA1c and ﬁxed DC
type treatment exhibited 8.3- and 1.65-fold better
outcomes, respectively, compared to those with higher
baseline HbA1c (coeﬃcient, 2.12; odds ratio, 8.3; 95% con-
ﬁdence interval (CI), 6.34–10.86) and free DC type treat-
ment (coeﬃcient, 0.5; odds ratio, 1.65; CI, 1.13–2.41);
however, patients with a longer diabetes duration exhibited
0.92-fold poorer outcomes (coeﬃcient, −0.08; odds ratio,
0.92; CI, 0.90–0.94) than did those with a shorter diabetes
duration. None of the other variables exhibited a signiﬁ-
cant association with outcomes.
3.3. Adverse Events. Two patients reported hypoglycemia,
and two patients reported elevated amylase or lipase from
the PMS data. However, there was no report of heart failure
or pancreatitis.
4. Discussion
Based on the analyses from three observational stu-
dies—including two 24-week PMS studies and one retrospec-
tive analysis of 50mg twice daily vildagliptin in combination
with metformin—in Korean patients with T2DM (VIC-
TORY study), we demonstrated three primary ﬁndings. First,
the use of vildagliptin as a second OHA signiﬁcantly achieved
reduction of HbA1c to the target level. Second, the clinical
eﬀectiveness of vildagliptin in combination with metfor-
min in clinical practice settings is similar to that observed
in RCTs. Third, dual therapy with vildagliptin and metfor-
min as ﬁxed DC induced better glycemic eﬀects compared
with free DC.
DPP-4 inhibitors have become commonly recommended
drugs for glycemic control in patients with T2DM because
these do not present the limitations exhibited by other OHAs
[5]. Although the clinical relevance of eﬀectiveness of DPP-4
inhibitors in terms of glycemic control remains unclear, such
relevance is usually established based on data collected via
RCTs. Nevertheless, the limitations of RCTs should be over-
come by conﬁrming these ﬁndings in real-world studies
under clinical practice settings [10, 11]. In particular, RCTs
narrowly deﬁne the inclusion and exclusion criteria to
address the aims of a study, and hence, enrolled participants
tend to be more highly motivated regarding their health
status and care. Thus, such an analysis would provide only
limited useful information regarding the eﬀectiveness of a
drug in real-world settings. In contrast, an observational
study conducted in routine practice settings is more likely
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Figure 2: Proportion of patients achieving the glycemic target (HbA1c≤ 7.0%) at 24 weeks. Free DC: free drug combination; Vilda/Met FDC:
vildagliptin +metformin ﬁxed dose combination.
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to enroll a broader patient population without any stringent
inclusion/exclusion criteria and can thus obtain valuable
information regarding the physician’s preference and ideas
as well as the real eﬃcacy and side eﬀects. However, at the
expense of internal validity, real clinical practice is character-
ized by the lack of randomization, selection by the investiga-
tors, and the absence of a centralized laboratory and intensive
monitoring. To address these limitations, there is an increas-
ing call for pragmatic trials [10, 11]. Thus, the shortcomings
of RCTs can be resolved through conﬁrmation of ﬁndings
via observational studies as part of routine care, which
could help both patients and healthcare providers make
better treatment decisions or improve adherence and
outcomes. In the present study, we aimed to assess the clini-
cal eﬀectiveness of vildagliptin with metformin in clinical
practice settings.
With regard to the glycemic eﬀectiveness of vildaglip-
tin—a potent and selective DPP-4 inhibitor—with metfor-
min, we found that this combination was eﬀective for
HbA1c reduction, was weight neutral, and did not present
any additional risk of hypoglycemia in RCTs [9, 12]. In a
recent meta-analysis, add-on treatment with vildagliptin
was found eﬀective in reducing HbA1c (−0.67%), in compar-
ison with placebo, in patients already treated with metfor-
min. Similarly, patients treated with vildagliptin in addition
to metformin exhibited no signiﬁcant diﬀerences in the gly-
cemic target achievement rates (HbA1c< 7%) in comparison
with those treated with other active comparators [9]. Data
from the VICTORY study are consistent with the key ﬁnd-
ings of these RCTs [9] and ﬁndings from previous real-life
vildagliptin studies conducted in other regions [13–15]. The
VICTORY study revealed that the mean reduction in HbA1c
with vildagliptin as an add-on to metformin was −0.8% at the
ﬁrst follow-up visit at 12 weeks, which further improved to
−1.0% at 24 weeks after treatment initiation. Interestingly,
this HbA1c reduction with vildagliptin is better than previ-
ously reported results from RCTs (9). DPP-4 inhibitors are
known to exhibit better glucose-lowering eﬀects in Asians
than in other ethnic groups. An earlier meta-analysis indi-
cated that DPP-4 inhibitors lowered the HbA1c levels by
0.9% in studies with more Asian participants [16]. These
ﬁndings might be explained by the varying contributions of
insulin secretory defects and insulin resistance in the patho-
physiological development of T2DM between Asians and
non-Asians [17].
In the present study, patients with better baseline HbA1c
and aged< 65 years exhibited better glycemic target achieve-
ment at 24 weeks; this could be explained by the shorter
duration of diabetes, better self-management, and remaining
β-cell function in this group [18, 19]. In addition, a larger
proportion of patients treated at hospitals achieved the glyce-
mic target compared with those treated at clinics; this may be
owing to the comprehensive management by an endocrinol-
ogy team (including an endocrinologist, nurse, and dietitian)
in hospital settings, which was also cited in another Korean
study [20].
Despite the progress in our understanding of the patho-
genesis of diabetes and the development of new drugs, the
present levels of care for patients with T2DM remain unsat-
isfactory [21]. Considering the complexity and progressive
nature of T2DM, monotherapy might not yield long-term
beneﬁts. Therefore, even at the time diabetes is diagnosed,
it might be appropriate to consider combination therapies
to achieve adequate glycemic control in patients with
T2DM [19]. In addition, the Global Partnership for Eﬀective
Diabetes Management recommends a more proactive
approach and advocates earlier use of combination therapy
in parallel with diet and exercise reinforcement for the man-
agement of T2DM [22]. Moreover, combination therapy in
T2DM should address the various pathophysiological mech-
anisms that cause hyperglycemia [23]. Metformin primarily
ameliorates insulin resistance, whereas DPP-4 inhibitors
improve pancreatic islet cell function by maintaining the
bioactivity of endogenous GLP-1. Therefore, coadministra-
tion of these two classes of antidiabetic medications could
yield synergistic eﬀects in the management of T2DM [24].
In fact, combination treatment with metformin and DPP-4
inhibitors induced a greater reduction in HbA1c levels com-
pared with monotherapy alone. In addition, combination
treatment showed good safety proﬁles, including a low risk
of hypoglycemia and weight neutrality [24]. Furthermore, a
meta-analysis of the initial combination of DPP-4 inhibitors
with metformin showed potential beneﬁts of this therapy on
glycemic outcomes, compared with metformin monotherapy
Table 2: Multivariate analysis for factors associated with glycemic target achievement (HbA1c< 7.0%) following vildagliptin treatment.
Variable Coeﬃcient SE of coeﬃcient Z value P value Odds ratio 95% CI
Gender 0.06 0.14 0.21 0.645 1.07 0.81–1.41
Age 0.01 0.01 2.84 0.092 1.01 1.00-1.02
Weight 0.00 0.01 0.15 0.697 1.00 0.99–1.02
Concurrent disease −0.25 0.23 1.13 0.288 0.78 0.49–1.24
Medical history 0.07 0.20 0.11 0.736 1.07 0.72–1.59
Concomitant medications (except for diabetes medications) 0.36 0.24 2.29 0.131 1.43 0.90–2.28
Duration of diabetes (1 year) −0.08 0.01 52.72 <0.001 0.92 0.90–0.94
HbA1c< 7.5% 2.12 0.14 237.15 <0.001 8.30 6.34–10.86
Fixed dose combination treatment 0.50 0.19 6.58 0.010 1.65 1.13–2.41
SE: standard error; CI: conﬁdence interval. Odds ratio of vidagliptin/metformin ﬁxed dose combination was calculated in comparison with the free
drug combination.
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alone, across a wide range of baseline HbA1c levels [25]. Met-
formin was also shown to enhance secretion of GLP-1, which
possibly improved the eﬀectiveness of DPP-4 inhibitors [26].
Moreover, drug adherence is a critical factor to consider
in the management of T2DM. The discontinuation of antidi-
abetic medication leads to a signiﬁcant cost burden on the
healthcare system and is frequently encountered in primary
care patients [15, 27]. Furthermore, patients with T2DM
often have metabolic comorbid conditions such as hyperten-
sion and dyslipidemia [28]. Management of such metabolic
comorbidities increases the pill burden on patients, which
could lead to an increased risk of medication-related
problems, such as drug-drug interactions and adverse events,
as well as poor treatment adherence [19, 27]. Hence, single-
pill ﬁxed DC medication may help patients with diabetes to
achieve their glycemic targets and promote adherence
through reduced pill and cost burdens [19]. Thus, ﬁxed DC
can enhance drug adherence and should be considered in
patients with chronic diseases such as T2DM to improve
drug adherence, which may consequently lead to better
clinical outcomes [27, 29, 30]. With regard to the clinical rel-
evance of ﬁxed DC therapy, in the present study, vildagliptin
plus metformin dual therapy as ﬁxed DC exhibited better
glycemic eﬀectiveness in our subgroup analysis and multivar-
iate analysis (Figure 2 and Table 2).
The strengths of the VICTORY study include the large
sample examined under clinical practice settings, which can
provide valuable additional information on vildagliptin.
However, the study also had certain limitations. First, the
study did not investigate the mechanism of action of vilda-
gliptin and did not seek to alter the treatment guidelines.
Second, this study had a nonrandomized, open-label, uncon-
trolled design, which may be associated with potential
observer and selection bias. The ﬁnal limitation was the open
nature of the trial, which allowed doctors to select any drug
for treatment, although this was expected given that the study
reﬂects actual clinical practice settings.
5. Conclusion
The results of this study conducted in real-world clinical
practice settings in Korea demonstrate that vildagliptin plus
metformin is a clinically reasonable option as a combination
therapy for patients with T2DM.
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